Inhibition of the activation of Hageman factor (factor XII) by beta 2-glycoprotein I

J Lab Clin Med. 1988 May;111(5):519-23.

Abstract

beta 2-Glycoprotein I (apolipoprotein H), a constituent of normal human plasma, has been shown to inhibit the generation of amidolytic activity in plasma that has been exposed to negatively charged agents. Studies with purified Hageman factor (factor XII) demonstrate that this inhibitory property is directed against the activation of Hageman factor. In this study beta 2-glycoprotein I inhibited the kaolin-induced generation of clot-promoting properties in solutions of Hageman factor. This effect was localized to an interaction between beta 2-glycoprotein I and kaolin. In contrast, once Hageman factor was activated by kaolin, its clot-promoting properties were not inhibited by beta 2-glycoprotein I. Further, beta 2-glycoprotein inhibited the generation of amidolytic activity against H-D-prolyl-L-phenylalanyl-L-arginine p-nitroanilide dihydrochloride in mixtures of Hageman factor and ellagic acid. The specificity of the action of beta 2-glycoprotein I was confirmed by its neutralization by immunoglobulin fractions of antiserums directed against this protein.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aniline Compounds / biosynthesis
  • Blood Coagulation / drug effects
  • Ellagic Acid / antagonists & inhibitors
  • Ellagic Acid / metabolism
  • Ellagic Acid / pharmacology
  • Factor VII / metabolism
  • Factor VII / physiology*
  • Glycoproteins / pharmacology*
  • Humans
  • Kaolin / antagonists & inhibitors
  • Kaolin / pharmacology
  • Male
  • Middle Aged
  • beta 2-Glycoprotein I

Substances

  • Aniline Compounds
  • Glycoproteins
  • beta 2-Glycoprotein I
  • Ellagic Acid
  • 4-nitroaniline
  • Kaolin
  • Factor VII